SCHEDULE: Dermata Therapeutics Stakeholder Reports 4.99% Ownership

Dermata Therapeutics, Inc. has filed a Schedule 13G detailing beneficial ownership of common stock by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have jointly reported beneficial ownership of 211,246 shares of Dermata Therapeutics, Inc. common stock.
• This ownership stake represents approximately 4.99% of the company's outstanding common stock as of March 31, 2026.
• The reported shares are primarily derived from the exercise of warrants held by Intracoastal Capital LLC.
• A blocker provision in one warrant prevents the reporting persons from exceeding 4.99% beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on ownership and does not provide financial performance or strategic updates that would typically influence investor sentiment.

Positives

• The reporting persons hold a significant stake, just under the 5% threshold that triggers more stringent reporting requirements.
• The filing clarifies the ownership structure and the basis for beneficial ownership through warrants.

Negatives

• The filing does not contain financial performance data, making it impossible to assess the company's financial health.
• The presence of a blocker provision suggests a strategic decision to limit direct control or influence to remain below a certain ownership threshold.

Risks

• The blocker provision in Intracoastal Warrant 4 limits the potential upside for the reporting persons if the stock price increases significantly, as they cannot exercise all warrants without exceeding the 4.99% ownership limit.
• The reliance on warrant exercise for ownership means the reporting persons' stake is contingent on the company's stock performance and their decision to exercise.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders who acquire more than 5% of a company's stock, or in this case, approach that threshold through derivative instruments like warrants. This filing indicates a notable interest in Dermata Therapeutics by these reporting persons.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership stakes, which can influence market perception and potential future corporate actions.
• Management: The reporting persons' significant stake may lead to increased engagement or scrutiny from management.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Dermata Therapeutics, Inc.

Key Dates

Keywords

Dermata Therapeutics, Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Warrants, SEC Filing, Common Stock